N-tert.-Butyl-N',N'-dimethyl-harnstoff | 53466-24-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 英文名称: N-tert.-Butyl-N',N'-dimethyl-harnstoff
• 英文别名: Urea, N-tert-butyl-N',N'-dimethyl-；3-tert-butyl-1,1-dimethylurea
• CAS: 53466-24-3
• 化学式: C₇H₁₆N₂O
• mdl: MFCD06154285
• 分子量: 144.217
• InChiKey: QTQNNPUOOYLCIW-UHFFFAOYSA-N

物化性质

• 沸点：
  259.8±9.0 °C(Predicted)
• 密度：
  0.916±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  二甲胺 、 叔丁基异氰酸酯 生成 N-tert.-Butyl-N',N'-dimethyl-harnstoff
  参考文献：
  名称：

  烷基对 N-H 拉伸振动和烷基脲旋转异构现象的空间效应

  摘要：

  研究了各种三烷基脲 R2UR' 在稀溶液中的自由 N-H 伸缩振动，以解决我们关于二烷基脲旋转异构的问题。在 R2UR' 的红外光谱中，其中 R 是异丙基或环己基，在反式 N-H 带的高频侧出现了一个额外的 N-H 带。还观察到R2UR'上R'基团的有效尺寸越大，附加带的强度变得越强。与二烷基脲的旋转异构相关的结论是，附加带是由 N-H 基团在骨架平面之外的形式产生的。

  DOI：

  10.1246/bcsj.48.2704

文献信息

• Modulators of muscarinic receptors
  申请人：Davies Robert

  公开号：US20070213315A1

  公开（公告）日：2007-09-13

  The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.

  本发明涉及毒蕈碱受体调节剂。本发明还提供包含此类调节剂的组合物，并使用这些方法治疗毒蕈碱受体介导的疾病。
• PIPERAZINE COMPOUNDS WITH A HERBICIDAL ACTION
  申请人：Hupe Eike

  公开号：US20090156553A1

  公开（公告）日：2009-06-18

  The invention relates to the use of piperazine compounds of formula (I) or the agriculturally useful salts of piperazine compounds of formula (I) as herbicides, the variables in formula (I) being defined as cited in the claims and the description.

  本发明涉及使用式(I)的哌嗪化合物或式(I)的农业有用盐作为除草剂，式(I)中的变量如权利要求书和说明书所述。
• INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY
  申请人：Claridge Stephen William

  公开号：US20090264440A1

  公开（公告）日：2009-10-22

  This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling and HGF receptor signaling. More particularly, the invention relates to compounds, compositions and methods for the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

  本发明涉及抑制蛋白酪氨酸激酶活性的化合物。具体而言，本发明涉及抑制生长因子受体蛋白酪氨酸激酶活性的化合物，从而抑制受体信号传导，例如抑制VEGF受体信号和HGF受体信号的传导。更具体地，本发明涉及抑制VEGF受体信号和HGF受体信号的化合物、组合物和方法。本发明还提供了治疗细胞增殖性疾病和状况的组合物和方法。
• Fused Aminopiperidine as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes
  申请人：Edmondson D. Scott

  公开号：US20080009510A1

  公开（公告）日：2008-01-10

  The present invention is directed to novel substituted fused aminopiperidines which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及一种新型的取代融合氨基哌啶，它们是二肽基肽酶-IV酶（“DPP-IV抑制剂”）的抑制剂，可用于治疗或预防二肽基肽酶-IV酶参与的疾病，如糖尿病，特别是2型糖尿病。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗二肽基肽酶-IV酶参与的这类疾病中使用这些化合物和组合物的用途。
• Processes and intermediates for preparing fused heterocyclic kinase inhibitors
  申请人：Raeppel Franck

  公开号：US20090286984A1

  公开（公告）日：2009-11-19

  This invention relates to processes and intermediates for manufacturing fused heterocyclic-type kinase inhibitor compounds, such as thienopyridine-based compounds, and to processes and intermediates for preparing intermediates that are useful in the manufacture of fused heterocyclic-type kinase inhibitor compounds, such as thienopyridine-based compounds, particularly at an industrial level.

  本发明涉及用于制造融合杂环型激酶抑制剂化合物的过程和中间体，例如噻吩并吡啶基化合物，并涉及用于制备在制造融合杂环型激酶抑制剂化合物，例如噻吩并吡啶基化合物中有用的中间体的过程和中间体，特别是在工业水平上。